We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 in Patients with Myasthenia Gravis

News   Jan 04, 2011

 
Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 in Patients with Myasthenia Gravis
 
 
 

RELATED ARTICLES

Safety and Efficacy Results From CRISPR/Cas9 Human Clinical Trials Are Positive

News

CRISPR Therapeutics and Vertex Pharmaceuticals have announced their interim safety and efficacy results from the CTX001 CRISPR/Cas9 gene-editing human clinical trials - and they're promising.

READ MORE

Hope for Improving Gut Health of HIV Sufferers

News

Damaged gut lining (leaky gut) in monkeys infected with chronic simian immunodeficiency virus (SIV), an HIV-like virus, was rapidly repaired within five hours of receiving Lactobacillus plantarum bacteria. The outcome lends hope that leaky gut, a common condition among HIV patients, could be effectively treated in the future.

READ MORE

Dangers of Mother's High-fat Diet for Unborn Child

News

High-fat maternal diets can cause life-long changes in the brain of the unborn offspring and it is unlikely that such damage can simply be reversed by a subsequent change of diet.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE